We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
신규 편입 · 포트폴리오 비중 0.03%
US analyst rating / recommendation change.
A material-event filing was submitted. Check the category (guidance / executives / M&A, etc.).
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
Consensus vs. actual, and revenue trend
Consensus PT $252.9 · 29 analysts
Stored first · Google News · Yahoo Finance (English)
AbbVie price target raised to $260 from $230 at UBS - TipRanks
AbbVie price target raised to $260 from $230 at UBS TipRanks
BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating - marketscreener.com
BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating marketscreener.com
BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating
ABBV Maintained by BMO Capital -- Price Target Raised to $300 - GuruFocus
ABBV Maintained by BMO Capital -- Price Target Raised to $300 GuruFocus
UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating
Why is AbbVie stock climbing today? - Investing.com
Why is AbbVie stock climbing today? Investing.com
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $3.77 | — | — | $16.76B | — | Scheduled |
| FY2026 Q1 | 2026. 05. 08. | Time TBD | — | $0.72 | — | — | $13.34B | Reported |
| FY2025 Q3 | 2025. 11. 04. | Time TBD | — | $2.41 | — | — | $41.23B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $1.53 | — | — | $26.77B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 16. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
| 2026. 05. 15. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2026. 05. 04. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
| 2026. 05. 02. | Guggenheim | — | Maintain | Buy → Buy | — | Guggenheim: Buy |
| 2026. 05. 01. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 05. 01. | Morgan Stanley | — | Maintain | Overweight → Overweight | — | Morgan Stanley: Overweight |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 178,418 | $38.8M | 0.03% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 114,712 | $26.21M | 0.04% | — | New position |